Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E18.77 EPS (ttm)1.59 Insider Own0.02% Shs Outstand6.34B Perf Week4.34%
Market Cap189.21B Forward P/E13.41 EPS next Y2.23 Insider Trans-3.06% Shs Float6.34B Perf Month2.37%
Income10.37B PEG8.94 EPS next Q0.55 Inst Own71.80% Short Float0.95% Perf Quarter3.40%
Sales50.33B P/S3.76 EPS this Y37.50% Inst Trans-0.10% Short Ratio2.40 Perf Half Y-1.22%
Book/sh12.03 P/B2.48 EPS next Y-0.67% ROA17.20% Target Price34.13 Perf Year-0.23%
Cash/sh5.37 P/C5.56 EPS next 5Y2.10% ROE38.70% 52W Range27.51 - 32.38 Perf YTD-0.03%
Dividend1.04 P/FCF17.71 EPS past 5Y6.80% ROI10.50% 52W High-7.54% Beta0.70
Dividend %3.49% Quick Ratio2.40 Sales past 5Y1.30% Gross Margin81.30% 52W Low8.83% ATR0.52
Employees77700 Current Ratio2.70 Sales Q/Q-1.50% Oper. Margin33.40% RSI (14)64.21 Volatility1.68% 1.72%
OptionableYes Debt/Eq0.49 EPS Q/Q-10.00% Profit Margin59.30% Rel Volume0.78 Prev Close29.84
ShortableYes LT Debt/Eq0.42 EarningsOct 28 BMO Payout22.50% Avg Volume25.00M Price29.94
Recom2.30 SMA204.14% SMA502.32% SMA2000.33% Volume14,239,120 Change0.34%
02-Jul-13Downgrade Standpoint Research Hold → Sell $24
15-Apr-13Reiterated Barclays Equal Weight $25 → $32
30-Jan-13Reiterated UBS Buy $29 → $31
30-Jan-13Reiterated Argus Buy $28 → $32
22-Jan-13Reiterated Barclays Equal Weight $24 → $25
27-Nov-12Downgrade MKM Partners Buy → Neutral $29 → $25
05-Oct-12Reiterated MKM Partners Buy $27 → $29
01-Nov-11Downgrade Standpoint Research Buy → Hold
07-Oct-11Initiated MKM Partners Buy $20.50
14-Sep-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
10-Aug-11Upgrade Argus Hold → Buy $21
05-Aug-11Upgrade Standpoint Research Hold → Buy $21
14-Mar-11Downgrade Standpoint Research Buy → Hold
03-Nov-10Downgrade Argus Buy → Hold
21-May-10Initiated Jefferies Buy $17.80
16-Dec-09Initiated UBS Buy
27-Apr-09Initiated Standpoint Research Buy $20
12-Feb-09Upgrade Leerink Swann Mkt Perform → Outperform
09-Feb-09Upgrade UBS Neutral → Buy
02-Feb-09Upgrade Credit Suisse Neutral → Outperform
30-Oct-14 05:04PM  Pfizer's Trumenba Gains Accelerated Approval in the U.S. Zacks
03:00PM  Viagra's Come-Hither Ad Campaign at BusinessWeek
12:03PM  U.S. SEC wants to distribute $602 mln SAC settlement to victims Reuters
09:00AM  Would Disney spin off Disneyland? Corporate breakup talk 'jumps the shark' Yahoo Finance
29-Oct-14 06:34PM  F.D.A. Approves Pfizers Trumenba, a Vaccine for a Rare Meningitis at New York Times
04:30PM  Stocks end modestly lower as Fed pulls plug on QE at CNBC
04:16PM  Pfizer meningitis vaccine wins U.S. approval Reuters
02:44PM  Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults Business Wire
02:25PM  Pfizer meningitis vaccine wins U.S. approval- FDA Reuters
10:07AM  Pfizer (PFE) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
09:22AM  Cramer's Mad Dash: US Steel leaner & meaner CNBC
08:30AM  Pfizers PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder Business Wire
28-Oct-14 08:44PM  Pfizer beats Q3 earnings forecasts - is that enough? CNBC
08:01PM  New Tax Rules Wont Stop Pfizer From Bidding U.S. Goodbye Bloomberg
06:46PM  Pfizer Q3 beats views Investor's Business Daily
04:20PM  Amgen has attractive, high-growth assets Market Realist
03:36PM  Pfizer Conference Call Highlights Benzinga
03:10PM  Pfizer Q3 Earnings Top Estimates Despite Generic Pressure Zacks
03:05PM  Stocks rally on earnings; Dow jumps 150 points at CNBC
02:39PM  Bonds hold losses after weak 2-year note auction at CNBC
12:45PM  Pfizer chief: tax inversions still have "meaningful value" at Financial Times
12:35PM  Pfizer Beats Earnings, But Lacks Year-over-Year EPS Growth Zacks
12:33PM  [$$] Pfizer Hasn't Ruled Out Potential Inversions, Chief Says at The Wall Street Journal
12:24PM  4 Stocks, 4 trades: BWLD, PFE, COH & KSS CNBC
09:31AM  Pfizer 3Q earnings up on emerging growth at USA TODAY
09:25AM  Pfizer beats sales and profit forecasts, mum on future deals Reuters
09:08AM  Cramer: Pfizer flatlining CNBC
09:02AM  PFIZER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
08:59AM  U.S. stocks: Futures trim gains after durable-goods orders at MarketWatch
08:53AM  Pfizers sales beats expectations even as top drugs lose patent protections at Fortune
08:19AM  Pfizer's 3Q beats on emerging market growth AP
07:22AM  Pfizer beats forecasts on demand for cancer drugs at CNBC
07:21AM  Pfizer beats third-quarter forecasts, mum on likely future deals Reuters
07:20AM  Pfizer Lowers Full-Year Sales Guidance on Competition at Bloomberg
07:17AM  Pfizer beats Q3 forecasts, mum on likely future deals Reuters
07:16AM  Pfizer's stock rallies after earnings, sales beat expectations at MarketWatch
07:07AM  Q3 2014 Pfizer Inc Earnings Release - Before Market Open CCBN
06:12AM  Novartis' precision M&A plan: CEO CNBC
05:54AM  Oil and earnings the main attractions (for now) at CNBC
27-Oct-14 06:56PM  Oil and earnings the main attractions (for now) at CNBC
06:56PM  Amgen Q3 Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
04:26PM  Merck good medicine? Talking Numbers
01:54PM  Health care stocks hitting new highs CNBC
01:00PM  Pfizer Walks From Remoxy; Is This The End Or Are There Ulterior Motives? Zacks Small Cap Research
12:40PM  Pain Therapeutics and Durect Stung by Pfizer Move at 24/7 Wall St.
11:37AM  Pfizer (PFE) Stock Falls After Dropping Pain Drug at TheStreet
10:15AM  4 Sector Stalwarts Enter the Earnings Hot Zone at Forbes
09:27AM  For A New Graduate Interested In A Drug R&D Job, Is Biotech Better Than Big Pharma? at Forbes
09:05AM  Pfizer ends agreement to develop Remoxy at MarketWatch
09:03AM  [$$] Pfizer Ends Pact to Develop Remoxy at The Wall Street Journal
08:59AM  Ambaraella, Pier One, Pfizer, Teva Pharmaceutical and Ligand Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
08:46AM  Pain Therapeutics, Durect shares tumble after Pfizer discontinues development pact at MarketWatch
08:15AM  Checkup on big pharma CNBC
08:05AM  DURECT Provides Update on REMOXY® and POSIDUR Programs PR Newswire
08:00AM  Pfizer to Discontinue Agreement on REMOXY (oxycodone) Extended-Release Capsules CII Business Wire
05:00AM  Tax Inversions Win When Government Lawyers Go Private Bloomberg
26-Oct-14 05:02AM  Energy, health care earnings to dominate week at MarketWatch
25-Oct-14 08:30AM  Get ready for a week full of earnings reports at USA TODAY
24-Oct-14 05:04PM  Why Pfizer's buyback may be bad medicine for the stock Talking Numbers
04:41PM  What to look for in Pfizer earnings at MarketWatch
04:20PM  Will Pfizer (PFE) Disappoint This Earnings Season? Zacks
12:35PM  Bristol-Myers Beats on Q3 Earnings, Maintains Guidance Zacks
12:10PM  Pfizer (PFE) $11 Billion Stock Repurchase Plan May End AstraZeneca (AZN) Bid at TheStreet
08:35AM  Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Zacks
08:05AM  Pfizer Stock Buyback Plan Just Too Large to Ignore It Is on Viagra at 24/7 Wall St.
07:31AM  Buyback blues hit the Street CNBC
06:58AM  Story Stocks from Briefing.com Briefing.com
04:11AM  Pfizer's $11 billion buyback plan deflates AstraZeneca bid hopes Reuters
23-Oct-14 06:36PM  Pfizer shares rise on $11B buyback program at USA TODAY
05:57PM  [$$] Pfizer Plans $11 Billion Stock Buyback at The Wall Street Journal
05:33PM  [video] U.S. Earnings Are `Going to Accelerate,' Cote Says at Bloomberg
04:56PM  Pfizer Announces Eye-Popping $11 Billion Share Buyback Plan Business Insider
04:38PM  Pfizer board authorizes $11 billion share repurchase Reuters
04:36PM  Pfizer Announces It Will Buy Back $11 Billion in Shares at Bloomberg
04:34PM  Pfizer approves $11B stock repurchase plan AP
04:26PM  Pfizer shares rise after new $11 billion share buyback program at MarketWatch
04:21PM  Taking Stock: Winners and Losers, Stock of the Day at Bloomberg
04:05PM  Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend Business Wire
10:30AM  Biggest Mergers & Acquisitions In The U.S. at Investopedia
08:57AM  U.S. court upholds patents on Pfizer's cancer drug Reuters
08:00AM  Pfizer Wins SUTENT® Patent Case In Delaware District Court Business Wire
22-Oct-14 10:23AM  Glaxo Considers ViiV IPO to Capitalize on HIV-Drug Sales at Bloomberg
21-Oct-14 08:13AM  Viagra Protects The Heart -- Now What? at Forbes
20-Oct-14 06:47PM  Can Valeant's Strong Q3 Entice Allergan? at Investor's Business Daily
05:14PM  Actavis Said to Compete With Sanofi for Omega Pharma Deal at Bloomberg
04:10PM  Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Zacks
02:54PM  Why Pfizer (PFE) Stock Remains a 'Buy' at TheStreet at TheStreet
02:20PM  3 Stocks Reiterated As A Buy: PFE, MU, CELG at TheStreet
11:00AM  Dow Jones (DJIA) Today: Pfizer (PFE) Lower at TheStreet
09:00AM  ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. PR Newswire
17-Oct-14 05:22PM  Pfizer's AstraZeneca pursuit knocked by Shire deal collapse at Financial Times
04:38PM  FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII Business Wire
03:38PM  Pfizer Loses a Bet on Removing Serious Warnings From its Chantix Pill at The Wall Street Journal
02:00AM  [$$] Panel Votes to Keep Strong Warning on Smoking-Cessation Drug at The Wall Street Journal
16-Oct-14 10:23PM  Baiyunshan's "Golden Spear" Targets Sweet Spot with Viagra Clone at Barrons.com
05:58PM  [$$] Panel Votes to Keep Strong Warning on Smoking-Cessation Drug at The Wall Street Journal
04:45PM  FDA panel votes to keep severe warning on Pfizer anti-smoking drug Reuters
04:03PM  FDA votes to keep black box warning on Pfizer anti-smoking drug Reuters
03:13PM  The Best-Selling Biologic Drugs at Forbes
03:07PM  Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals at Investor's Business Daily
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company's Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company's Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM
YOUNG JOHN DGroup PresidentMar 17Sale31.389,000282,42099,647Mar 18 09:33 AM
PFIZER INC10% OwnerMar 12Buy11.00272,7272,999,9971,235,330Mar 14 03:27 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale32.5967,5852,202,872173,637Mar 05 05:36 PM
Dolsten MikaelPresident R&DMar 04Sale32.5835,7891,165,929344,571Mar 05 05:36 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 04Sale32.555,082165,419171,756Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Option Exercise26.2075,5001,978,100274,699Mar 05 05:37 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerMar 03Sale32.0297,8613,133,674176,838Mar 05 05:37 PM
READ IAN CChairman & CEOFeb 26Option Exercise12.70324,9324,126,6361,410,536Feb 28 04:52 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise12.70130,8751,662,113312,499Feb 28 04:52 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise12.7057,586731,342116,884Feb 28 04:52 PM
BOURLA ALBERTGroup PresidentFeb 26Option Exercise12.7021,482272,82192,447Feb 28 04:52 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise12.7056,411716,420228,878Feb 28 04:52 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise12.70324,9324,126,636615,673Feb 28 04:52 PM
HILL CHARLES HExecutive Vice PresidentFeb 26Option Exercise12.7034,731441,084104,046Feb 28 04:52 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise12.7034,568439,014120,562Feb 28 04:52 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12740,480Feb 28 04:52 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 26Option Exercise12.7029,695377,12783,716Feb 28 04:52 PM
OLSON LAURIE JExecutive Vice PresidentFeb 26Option Exercise12.7031,772403,50468,167Feb 28 04:52 PM
PFIZER INC10% OwnerFeb 04Buy8.00227,2611,818,0881,794,803Feb 06 03:53 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.82131,8104,062,225356,451Jan 14 07:13 PM
DAMELIO FRANK AExecutive Vice PresidentJan 13Sale30.8628,190869,817328,261Jan 14 07:13 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Option Exercise26.2092,0002,410,400152,447Nov 18 03:31 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 14Sale32.1092,0002,953,06360,447Nov 18 03:31 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerNov 01Sale31.2010,000311,985174,841Nov 04 03:59 PM